04 Sep
2017
22:30 E.S.T.

Cellectis to Participate in Upcoming Investor Conferences

Read more

04 Sep
2017
22:15 E.S.T.

Cellectis Reports Clinical Hold of UCART123 Studies

Read more

17 Aug
2017
16:30 E.S.T.

Cellectis’ UCART123 Administered to First Patient with BPDCN in Phase I Clinical Trial at MD Anderson Cancer Center

Read more

02 Aug
2017
16:30 E.S.T.

Cellectis Reports Financial Results for 2nd Quarter and First Six Months 2017

Read more

25 Jul
2017
16:01 E.S.T.

Calyxt Announces Full Exercise of Over-Allotment Option and Closing of its Initial Public Offering

Read more

24 Jul
2017
16:30 E.S.T.

Cellectis Granted Patent for CRISPR Use in T-Cells

Read more

19 Jul
2017
18:54 E.S.T.

Calyxt Announces Pricing of $56.0 Million Initial Public Offering

Read more

10 Jul
2017
07:08 E.S.T.

Calyxt Announces Proposed Initial Public Offering of $100.0 Million

Read more

28 Jun
2017
16:30 E.S.T.

Cellectis Appoints Rainer Boehm, M.D. and Hervé Hoppenot to Board of Directors

Read more

27 Jun
2017
16:30 E.S.T.

First in Human Administration of UCART123 in Cellectis’ AML Phase I Clinical Trial at Weill Cornell Medicine, NewYork-Presbyterian Hospital

Read more